| Naslov: | Real-world data on detection of germline and somatic pathogenic/likely pathogenic variants in BRCA1/2 and other susceptibility genes in ovarian cancer patients using next generation sequencing |
|---|
| Avtorji: | ID Stegel, Vida (Avtor)
ID Blatnik, Ana (Avtor)
ID Škof, Erik (Avtor)
ID Šetrajčič Dragoš, Vita (Avtor)
ID Krajc, Mateja (Avtor)
ID Gregorčič, Brigita (Avtor)
ID Škerl, Petra (Avtor)
ID Strojnik, Ksenija (Avtor)
ID Klančar, Gašper (Avtor)
ID Banjac, Marta (Avtor)
ID Žgajnar, Janez (Avtor)
ID Ravnik-Oblak, Maja (Avtor)
ID Novaković, Srdjan (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/14/6/1434
 PDF - Predstavitvena datoteka, prenos (2,35 MB)
MD5: DF9297614111EC2463CB1324BFEB404E
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Detection of germline and somatic pathogenic/likely pathogenic variants (PV/LPV) in BRCA genes is at the moment a prerequisite for use of PARP inhibitors in different treatment settings of different tumors. The aim of our study was to determine the most appropriate testing workflow in epithelial ovarian cancer (EOC) patients using germline and tumor genotyping of BRCA and other hereditary breast and/or ovarian cancer (HBOC) susceptibility genes. Consecutive patients with advanced non-mucinous EOC, who responded to platinum-based chemotherapy, were included in the study. DNA extracted from blood and FFPE tumor tissue were genotyped using NGS panels TruSightCancer/Hereditary and TruSight Tumor 170. Among 170 EOC patients, 21.8% had BRCA germline or somatic PV/LPV, and additionally 6.4% had PV/LPV in other HBOC genes. Sensitivity of tumor genotyping for detection of germline PV/LPV was 96.2% for BRCA genes and 93.3% for HBOC genes. With germline genotyping-only strategy, 58.8% of HBOC PV/LPV and 68.4% of BRCA PV/LPV were detected. By tumor genotyping-only strategy, 96.1% of HBOC PV/LPV and 97.4% of BRCA PV/LPV were detected. Genotyping of tumor first, followed by germline genotyping seems to be a reasonable approach for detection of PV/LPV in breast and/or ovarian cancer susceptibility genes in non-mucinous EOC patients. |
|---|
| Ključne besede: | BRCA, ovarian cancer, tumor genotyping, HBOC |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.03.2022 |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 1434-1-1434-17 |
|---|
| Številčenje: | Vol. 14, no. 6 |
|---|
| PID: | 20.500.12556/DiRROS-15446  |
|---|
| UDK: | 616-07 |
|---|
| ISSN pri članku: | 2072-6694 |
|---|
| DOI: | 10.3390/cancers14061434 |
|---|
| COBISS.SI-ID: | 100563715 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 12. 3. 2022;
|
|---|
| Datum objave v DiRROS: | 06.09.2022 |
|---|
| Število ogledov: | 926 |
|---|
| Število prenosov: | 475 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
